Omalizumab: NICE to USE you to LOSE you NICE

Thorax

Volumn 68, Issue 1, 2013, Pages 7-8

  Bush, Andy ^a   Pavord, Ian D ^b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB;

ASTHMA; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; DRUG USE; EDITORIAL; HEALTH CARE INDUSTRY; HUMAN; MEDICAL PRACTICE; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 84871370456     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202969     Document Type: Editorial

References (14)

1. Bush A, Saglani S. Management of severe asthma in children. Lancet 2010;376:814-25.
2. Bracken M, Fleming L, Hall P, et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child 2009;94:780-4.
3. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341 -51.
4. Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol 2012;129:974-82.
5. Heaney LG, Brightling CE, Menzies-Gow A, et al. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010;65:787 -94.
6. Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. Thorax 2011;67:268-70.
7. Bush A, Lenney W, Spencer D, et al. Not NICE: a better way forward? Arch Dis Child 2011;96:907-8.
8. Garcia G, Magnan A, Girodet PO, et al. A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma (abstract). Eur Respir J 2012;40:856s.
9. Pavord ID, Bush A. Anti-IgE for asthma in inner-city children. N Engl J Med 2011;364:2556-7.
10. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66:910- 17.
11. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
12. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
13. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98.
14. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway infl ammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93.